Medtronic Takes Aim At Implantable Device Infections With TYRX Buy

The $160 million cash acquisition fits with the firm’s efforts to fashion itself into a health care services and solutions company, rather than a pure device firm. TYRX makes anti-bacterial envelopes for implanted devices, and has FDA clearances for use of its products with cardiac implantable electronic devices and spinal cord neurostimulators.